Optimistic Buy Rating for Kronos Bio Amid Positive KB-0742 Trial Progress and Expanding Oncology Pipeline
Kronos Bio Analyst Ratings
HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $2.25
HC Wainwright & Co. : The Kronos Bio (KRON.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $2.50 to $2.25.
Buy Rating Affirmed for Kronos Bio Amid Promising KB-0742 Data and Solid Financial Footing
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Axsome Therapeutics (AXSM) and Sotera Health (SHC)
Piper Sandler Remains a Buy on Kronos Bio (KRON)
Buy Rating Affirmed for Kronos Bio Amid Restructuring and Promising KB-0742 Clinical Data
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating
Kronos Bio Receives Buy Rating From Analyst Amid Promising Pipeline Developments
HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $2.5
Kronos Bio Analyst Ratings
TD Cowen Sticks to Its Buy Rating for Kronos Bio (KRON)
HC Wainwright & Co. Reiterates Buy on Kronos Bio, Maintains $9 Price Target
Kronos Bio Analyst Ratings
Strategic Financial Management and Promising Clinical Trials Underpin Buy Rating for Kronos Bio
Kronos Bio (KRON) Gets a Buy From TD Cowen
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Quest Diagnostics (DGX) and UnitedHealth (UNH)
HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $9